Interní Med. 2005; 7(7): 332-335

Diabetes mellitus and cardiovascular diseases

MUDr. Denisa Janíčková Ždárská
I. Interní klinika 2. LF UK a FN Motol, Praha

Diabetes mellitus is a serious metabolic disease that is associated with increased cardiovascular morbidity and mortality. Both type 1 and 2 diabetes increase cardiovascular risk 2-4 fold compared with the general population. This increase in the risk of macrovascular complications is attributed to multiple factors, including classic risk factors such as arterial hypertesion, obezity, dyslipidemia and also hyperglycaemia, insulin resistance, glycation and oxidation of proteins, procoagulated status and the other. In the text there are shown patophysiologic mechanism of macroangiopatic complications and the ways of influence which go to decrease of cardiovascular morbidity and mortality.

Keywords: Key words: cardiovascular (macroangiopatic) complications, diabetes mellitus type 1 and type 2, insulin resistance.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janíčková Ždárská D. Diabetes mellitus and cardiovascular diseases. Interní Med. 2005;7(7):332-335.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Albert MA, Danielson, Rifai N, Ridker PM, for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin iflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA, 2001; 286: 64-70. Go to original source... Go to PubMed...
    2. American Diabetes Association. Clinical practice recommendations 2002. Diabet Care. 2002, 25 (suppl 1): S1-S147.
    3. Cardiovascular disease morbidity and mortality in patients with type 1 diabetes mellitus: management strategies. Soedamah-Muthu SS, Stehouwer CD. Treat Endocrinol. 2005; 4 (2): 75-86.
    4. Cecilia C, Low Wang, Marc L Goalstone, et al. Molecular mechanism of insulin resistance that impact cardiovascular biology. Diabetes 2004; 53, 2735-2740. Go to original source... Go to PubMed...
    5. Dahlof B, Devereux RB, Kjedsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    6. Grandy SM, Garber A, Goldberg R, et al. Prevention conference VI: diabetes and cardiovascular disease: writing group IV: lifestyle and medical management of risk factors. Circulation 2002; 105, 153e-158e. Go to original source... Go to PubMed...
    7. Haffner SM, Lehto S, Ronnemaat T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998; 23, 339 (4): 229-234. Go to original source... Go to PubMed...
    8. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000, 342: 145-153. Go to original source... Go to PubMed...
    9. Heart Protection Study Collaborative Group.MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016. Go to original source... Go to PubMed...
    10. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 2001, 52: 239-2572. Go to original source... Go to PubMed...
    11. Pickup JC, Williams G. Textbook of diabetes, 3rd ed. Oxford. Blaskwell-Science, 2003.
    12. Riker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836-843. Go to original source... Go to PubMed...
    13. Shulman GI. Cellular mechanism of insulin resistance. J. Clin Invest 2000; 106: 171-176. Go to original source... Go to PubMed...
    14. Perušičová J. Můžeme snížit riziko kardiovaskulárních chorob u diabetiků 2. typu? Diabetes and its complications 2004, ročník 2, číslo 4.
    15. UK Prospective Diabets Study (UKPDS) Group. Effect of intensive blood - glucose control with metformin on complications in overweight patiets with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865. Go to original source...
    16. 1999 World Health Organization - International Society of Hypertension Guidelies for Management of Hypertension. Guidelines Subcommittee. J. Hypertens 1999, 17: 151-183. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.